{
    "clinical_study": {
        "@rank": "137978", 
        "acronym": "MORDOR", 
        "arm_group": [
            {
                "arm_group_label": "Biannual mass oral azithromycin", 
                "arm_group_type": "Active Comparator", 
                "description": "Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.\nChildren aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years"
            }, 
            {
                "arm_group_label": "Biannual mass oral placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.\nChildren aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years"
            }
        ], 
        "brief_summary": {
            "textblock": "Our long-term goal is to more precisely define the role of mass azithromycin treatments as\n      an intervention for reducing childhood mortality. We propose a single multi-site\n      (multi-country), cluster-randomized trial comparing communities randomized to oral\n      azithromycin with those randomized to placebo. We hypothesize that mass azithromycin\n      treatments will reduce childhood mortality."
        }, 
        "brief_title": "Mortality Reduction After Oral Azithromycin: Mortality Study", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Childhood Mortality", 
        "detailed_description": {
            "textblock": "We will assess childhood mortality over two years, comparing communities where children aged\n      1-60 months receive biannual oral azithromycin (\"Azithromycin\" arm), to communities where\n      the children receive biannual oral placebo (\"Control\" arm).\n\n      This is a cluster-randomized trial; at each site, communities within a contiguous area of\n      300,000 to 600,000 individuals will be randomized to azithromycin or placebo using simple\n      random sampling.\n\n      Specific Aims\n\n      Specific Aim 1: To test the hypothesis that mass distributions of oral azithromycin targeted\n      to 1-60 month old children reduces childhood mortality, in a cluster-randomized trial\n\n      Specific Aim 2: To assess the cost-effectiveness of mass azithromycin in reducing childhood\n      mortality"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Communities\n\n          -  The community location in target district.\n\n          -  The community leader consents to participation in the trial\n\n          -  The community's estimated population is between 200-2,000 people.\n\n          -  The community is not in an urban area.\n\n        Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as\n        assessed via biannual census.\n\n        Exclusion Criteria:\n\n        Individuals\n\n        - Refusal of village chief (for village inclusion), or refusal of parent or guardian (for\n        individual inclusion)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Months", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "227000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047981", 
            "org_study_id": "OPP1032340-A"
        }, 
        "intervention": [
            {
                "arm_group_label": "Biannual mass oral azithromycin", 
                "description": "Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years", 
                "intervention_name": "Azithromycin", 
                "intervention_type": "Drug", 
                "other_name": "Zithromax"
            }, 
            {
                "arm_group_label": "Biannual mass oral placebo", 
                "description": "Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Childhood mortality", 
            "Azithromycin", 
            "Mass treatment", 
            "Infection", 
            "Verbal Autopsy"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tom.lietman@ucsf.edu", 
                    "last_name": "Thomas Lietman, MD", 
                    "phone": "415-502-2662"
                }, 
                "contact_backup": {
                    "email": "Nicole.Stoller@ucsf.edu", 
                    "last_name": "Nicole E Stoller, MPH", 
                    "phone": "415-476-2460"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF Proctor Foundation"
                }, 
                "investigator": {
                    "last_name": "Tom M Lietman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "shwest@jhmi.edu", 
                    "last_name": "Sheila West, PhD", 
                    "phone": "410-955-2606"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kkalua@medcol.mw", 
                    "last_name": "Khumbo Kalua", 
                    "phone": "+265 999958176"
                }, 
                "facility": {
                    "address": {
                        "city": "Blantyre", 
                        "country": "Malawi"
                    }, 
                    "name": "College of Medicine at the University of Malawi, Blantyre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mohamedsalissoukane@yahoo.fr", 
                    "last_name": "Mohamed Salissou Kane", 
                    "phone": "+227 20 73 28 57"
                }, 
                "facility": {
                    "address": {
                        "city": "Niamey", 
                        "country": "Niger"
                    }, 
                    "name": "The Carter Center, Niger"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hmkocha@yahoo.com, ktp.2012@yahoo.com", 
                    "last_name": "Harran Mkocha", 
                    "phone": "+255 26232 31 33"
                }, 
                "facility": {
                    "address": {
                        "city": "Kongwa", 
                        "country": "Tanzania"
                    }, 
                    "name": "Kongwa Trachoma Project"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Robin.Bailey@lshtm.ac.uk", 
                    "last_name": "Robin Bailey, MRCP, PhD", 
                    "phone": "020 7927 2914"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "London School of Hygiene & Tropical Medicine"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Malawi", 
                "Niger", 
                "Tanzania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Mortality Trial", 
        "overall_contact": {
            "email": "tom.lietman@ucsf.edu", 
            "last_name": "Tom M Lietman, MD", 
            "phone": "415-502-2662"
        }, 
        "overall_contact_backup": {
            "email": "Nicole.Stoller@ucsf.edu", 
            "last_name": "Nicole E Stoller, MPH", 
            "phone": "415-476-2460"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Tom M Lietman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Nicole E Stoller, MPH", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board", 
                "Niger: Institutional Review Board", 
                "Malawi: College of Medicine Research and Ethics Committee", 
                "Tanzania: Ethical Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the SAP.", 
            "measure": "All-cause Mortality Rate in children aged 1-60 months", 
            "safety_issue": "No", 
            "time_frame": "24 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047981"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "measure": "Cost-effectiveness of mass azithromycin administration, per averted childhood death", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "All-cause and cause-specific health clinic visits in 1-60 month-old children", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Bill and Melinda Gates Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}